US Pharma MarketingThe post Akagera announces positive Phase I data of AKG-100 in tuberculosis appeared first on Clinical Trials Arena.
Akagera announces positive Phase I data of AKG-100 in tuberculosis
Akagera Medicines has reported positive data from the SAD segment of its first-in-human Phase I trial of AKG-100, an investigational long-acting IV therapeutic targeting tuberculosis, including DR-TB. The post Akagera announces positive Phase I data of AKG-100 in tuberculosis appeared first on Clinical Trials Arena .
Akagera Medicines has reported positive data from the SAD segment of its first-in-human Phase I trial of AKG-100, an investigational long-acting IV therapeutic targeting tuberculosis, including DR-TB.
Source: Clinical Trials Arena